Expanding Treatment Options for Newly Diagnosed Multiple Myeloma: Proteasome Inhibitors, Immunomodulatory Drugs, and Other Targeted Therapies

Expanding Treatment Options for Newly Diagnosed Multiple Myeloma: Proteasome Inhibitors, Immunomodulatory Drugs, and Other Targeted Therapies
Expanding Treatment Options for Newly Diagnosed Multiple Myeloma: Proteasome Inhibitors, Immunomodulatory Drugs, and Other Targeted Therapies
CME, CPE
Sagar Lonial, MD, FACP
Release Date: September 27, 2017
Expiration Date: September 27, 2018

In recent years, advances in treatment have resulted in significantly improved outcomes and prognoses in patients with multiple myeloma; much of this research, however, was focused on the population of patients with relapsed or refractory disease. Today, a growing compendium of data and ongoing research is evaluating treatment options and management approaches specifically in patients with newly diagnosed multiple myeloma. Topics being evaluated include: when to treat smoldering versus symptomatic myeloma; factors to consider when selecting an induction regimen from among the current standard of care to new options investigated in the clinical trial setting; and the role of high-dose therapy consolidation and maintenance therapy. In this activity, Dr. Lonial summarizes the current state of research in each of these areas, and discusses the potential impact of the application of this information on improving outcomes and progression-free survival in patients with newly diagnosed multiple myeloma.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Takeda Oncology
Begin, Earn CreditView Only, No Credit